Kitov Pharmaceuticals Holdings Ltd. : American Depositary Receipts Securities Litigation
On or around 09/19/2018 (Settlement preliminarily approval)
Filing Date: February 07, 2017
According to the law firm press release, Kitov is a clinical development stage biopharmaceutical company that develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The Company’s lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate, that has completed its Phase III clinical study.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company and its Chief Executive Officer (“CEO”) Isaac Israel published misleading information concerning the conduct of the Company’s clinical trials for its lead drug candidate KIT-302; and (ii) as a result of the foregoing, Kitov’s public statements were materially false and misleading at all relevant times.
An amended Complaint was filed on June 19, 2017. Defendants filed a Motion to Dismiss the amended Complaint on August 2. On March 20, 2018, the Court issued an Order granting in part and denying in part the Defendants' Motion to Dismiss. On July 27, the parties entered into a Stipulation of Settlement. The Court granted preliminary approval of the Settlement on September 19.
Company & Securities Information
Defendant: Kitov Pharmaceuticals Holdings Ltd.
Industry: Biotechnology & Drugs
Ticker Symbol: KTOV
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Ameya Pilgaonkar, et al. v. Kitov Pharmaceuticals Holdings Ltd., et al.
COURT: S.D. New York
DOCKET #: 17-CV-00917
JUDGE: Hon. Lorna G. Schofield
DATE FILED: 02/07/2017
CLASS PERIOD START: 11/20/2015
CLASS PERIOD END: 02/03/2017
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Goldberg Law PC (Los Angeles) 1999 Avenue of the Stars, Goldberg Law PC (Los Angeles), CA 90067 1-800-977-7401 1-800-536-0065 ·